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Although in its infancy, organized screening for colorectal cancer
(CRC) in the general population is increasing at regional and
national levels. Documenting and describing these initiatives
is critical to identifying, sharing and promoting best practice in
the delivery of CRC screening. Subsequently, the International
Colorectal Cancer Screening Network (ICRCSN) was established
in 2003 to promote best practice in the delivery of organized
screening programs. The initial aim was to identify and document
organized screening initiatives that commenced before May 2004.
Each identiﬁed initiative was sent 1 questionnaire per screening
modality: fecal occult blood test, ﬂexible sigmoidoscopy or total
colonoscopy. Information was collected on screening methodol-
ogy, testing details and initiative status. In total, 35 organized ini-
tiatives were identiﬁed in 17 countries, including 10 routine popu-
lation-based screening programs, 9 pilots and 16 research proj-
ects. Fecal occult blood tests were the most frequently used
screening modality, and total colonoscopy was seldom used as a
primary screening test. The eligible age for screening ranged
from 40 years old to no upper limit; most initiatives included par-
ticipants aged 50 to 64. Recruitment was usually done by a mailed
invitation or during a visit to a family physician. In conclusion,
this is the ﬁrst investigation describing the delivery of CRC
screening protocols to various populations. The work of the
ICRCSN is enabling valuable information to be shared and a
common nomenclature to be established.
' 2007 Wiley-Liss, Inc.
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Worldwide each year, more than 940,000 new cases of colorec-
tal cancer (CRC) are diagnosed and nearly 500,000 people die
from the disease.1 CRC is the third most common cancer in both
men and women worldwide, and the second most common cancer
in the industrialized world.2
Early detection of CRC has been shown to improve outcomes
through the detection of early-stage cancers and precursor
lesions.3 Because early-stage disease frequently is asymptomatic,
screening of the general population could decrease CRC incidence
and mortality. There are 3 frequently used screening modalities:
fecal occult blood test (FOBt), which reveals traces of blood in
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stool samples (an early sign of CRC); ﬂexible sigmoidoscopy
(FS), which involves visual inspection of the distal bowel for pol-
yps and cancers; and total colonoscopy (TC), which visualizes the
entire bowel and therefore is a more invasive examination.
Biennial screening using a guaiac FOBt (gFOBt) was found to
decrease mortality by 15% after 13 years of follow-up in a large
randomized trial in Funen, Denmark,4,5 and by 13% after an 11-
year follow-up in Nottingham, United Kingdom.6,7 Neither study
found a decrease in incidence, although follow-up continues. A
more complex trial in Minnesota, USA, compared annual and
biennial screening using FOBt.8 After an 18-year follow-up, mor-
tality decreased by 33% in participants screened annually, and
21% in those screened biennially.9 Reductions in incidence of
20% and 17% were also observed for annually and biennially
screened individuals, respectively.10
Four large-scale randomized clinical trials are evaluating FS as
a screening tool. Baseline ﬁndings have been published showing
that FS screening is safe (no major complications and relatively
few perforations) and acceptable to the population.11–15 A ran-
domized clinical trial of FS screening in Telemark, Norway
reported an 80% reduction in CRC incidence rates with a 13-year
follow-up. The numbers in this study were small, however.16
Although TC detects adenomas beyond the reach of FS no
randomized clinical trials have been conducted. However, the
U.S. National Polyp Study reported a reduction in the incidence of
CRC when comparing those who had a complete colonoscopy
where all adenomas were removed, to 3 reference groups: patients
with polyps 1 cm who declined to undergo surgery; patients who
had all rectal adenomas removed; and the ﬁnal cohort was a sam-
ple of the general population.17
A country’s screening initiatives need to be adapted to suit its
population size, health care system and methods of funding. How-
ever, it will be beneﬁcial to collect and share implementation and
performance data among countries. Information on the effective-
ness of technologies and methodologies can beneﬁt existing pro-
grams. It can also provide insights and guidance to those in the
planning stages of screening initiatives. Additionally, comparing
the effectiveness of different screening modalities within a coun-
try could inform decision-making about an appropriate national
screening protocol speciﬁc to the needs of that country. To facili-
tate the sharing of such information and comparisons, it is im-
portant to have a common nomenclature and for initiatives to be
collecting the appropriate data. However, because colorectal
screening is in its infancy in most countries, a common language
to describe the screening process and common measures by which
quality can be examined for all tests and types of programs have
yet to be established.
In June 2002, the International Union Against Cancer and the
American Cancer Society sponsored an international workshop in
Oslo, Norway, on facilitating screening for CRC.18 From this
meeting it was clear that a great deal of CRC screening activity
was taking place worldwide, and that it would be beneﬁcial to
describe the activity and build a network to share experience and
knowledge. Subsequently, the Centers for Disease Control and
Prevention and the American Cancer Society supported a collabo-
rative effort with Cancer Research UK to develop the International
Colorectal Cancer Screening Network (ICRCSN).
The ﬁrst aim of the ICRCSN was to identify and document the
status of organized screening initiatives, and that information is
reported in the present article. As a next step, the ICRCSN is
focused on establishing a consensus minimum set of screening
program descriptors and quality assurance measures with common
deﬁnitions and measurement metrics to enable program evaluation
and comparisons.
Methods
Known colorectal screening initiatives in progress (either
screening or in follow-up after screening) as of May 2004 were
contacted to assess their interest and potential for involvement in
the ICRCSN. Initial approaches were made through personal
knowledge of grant holders, conference contacts and literature and
internet searches. Each contact was asked to identify other initia-
tives. The lead of each initiative was identiﬁed and a working
group, composed of 11 members from 5 countries, was convened
to develop the methodology and principles for the survey.
To be included in the Network, screening initiatives were
required to meet a set of criteria. Initiatives were required to be
carrying out screening of the general population, targeting asymp-
tomatic people within a deﬁned age range, and in an organized
manner, as deﬁned by the International Agency for Research on
Cancer (IARC).19 Characteristics of an organized screening pro-
gram include an explicit policy with speciﬁed age categories,
method and interval for screening; a deﬁned target population; a
management team responsible for implementation; a health care
team for decisions and care; a quality assurance structure; and a
method for identifying cancer occurrence in the target population.
Initiatives were further classiﬁed as (i) programs in which screen-
ing is offered as part of routine health care; (ii) pilot studies car-
ried out in a limited population for a limited time to assess feasi-
bility, with a view to possibly extending to a program, or (iii)
research projects with a ﬁxed sample size and duration aimed at
answering a speciﬁc question. If an initiative used more than 1
screening modality, then each modality (or combination of modal-
ities offered to the same participant) was considered a separate ac-
tivity.
Between November 2003 and March 2004, 2 questionnaires
were designed to elicit information about screening initiatives in
the countries and regions represented by members of the ICRCSN.
The questionnaires were patterned after instrumentation developed
by the International Breast Cancer Screening Network to charac-
terize breast cancer screening activities among participating coun-
tries (http://appliedresearch.cancer.gov/ICSN/). The ﬁrst question-
naire, the National Questionnaire, asked about a country’s policies
and guidelines on CRC screening, as well as for speciﬁc informa-
tion about screening initiatives. The questionnaire included
details of modality, target population and some information about
protocol.
In addition to the National Questionnaire, modality-speciﬁc
questionnaires were designed for FOBt, FS and TC. The question-
naires contained 6 sections: contact details for activity leads and
other individuals involved in the activity, screening methodology,
testing details, status of the initiative/activity, screening perform-
ance and outcomes and quality assurance.
Drafts were reviewed by a subgroup of the working group and
pilot tested with a sample of initiative representatives of the
ICRCSN. The ﬁnalized questionnaires were distributed in March
2004 via email to representatives from all known initiatives.
An international workshop for survey respondents was held in
London in May 2004. Results of the survey were described and
discussed. Areas requiring classiﬁcation or conﬁrmation were
identiﬁed and reﬁnements made. Unclear responses to the ques-
tionnaire were clariﬁed by subsequent communications with the
initiative leads.
Results
A total of 35 organized independent initiatives delivering CRC
screening to asymptomatic populations were identiﬁed. These
were then analyzed by geographic location, screening modality
and type of initiative.
Geographical variation
The 35 organized initiatives were identiﬁed in 17 countries in 3
geographic regions (as deﬁned by the World Health Organization,
or by proximity where necessary): Europe (n 5 23), the Americas
(n 5 6) and the Western Paciﬁc (n 5 6) (Table I). Initiatives were
funded primarily by public funds, usually from central and local
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TABLE I – A DESCRIPTION OF EACH INITIATIVE, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH ORGANIZATION WHERE POSSIBLE, 2004
Country
Initiative
type Modality Name of initiative Region(s) Target population Age range
Target
population
in age range
Funding
source
Year
activity
began
Total screening
episodes before
May 2004
EUROPE
Belgium Research FS Screening for CRC Using
Sigmoidoscopy
All HMO members 50–75 10,000 S 1993 1,912
Czech
Republic
Program FOBt National Program of
Screening for CRC
All Population visiting FP 501 3,700,000 CG, HI 2001 1,000,000
Denmark Research FOBt Randomized Study of
Screening for CRC
with FOBt
Funen Resident population 45–75 140,000 PC, CG 1985 128,703
France Research FOBt Burgundy Study Burgundy,
Saoˆne-et-Loire
Resident population 45–74 155,000 CG, HI 1988 45,642
Pilot FOBt National Program for
CRC
22 Departements Resident population 50–74 4,500,000 CG, HI 2003 716,5221
Israel Program FOBt CHS National CRC
Screening Program
All HMO members 50–74 700,000 HMO 1993 60,000
Italy Research FS SCORE Arezzo, Biella,
Genova, Milan,
Rimini, Turin
Volunteers 55–64 256,000 PC 1995 9,999
Pilot FOBt SCORE 2 Biella, Florence,
Milan, Rimini,
Turin
Resident population 55–64 122,000 LG, PC 1999 5,120
FS 9,525
Program FOBt NHS Funded Regional
Screening Program
Tuscany Residential population
of 7 local health
units
50–70 969,000 LG 2000 259,227
Program FOBt NHS Funded Regional
Screening Program
Veneto Resident population of 4
local health units
50–69 173,000 LG 2002 42,800
Research FOBt Accademia Multidisciplinare
Oncologia Digestiva
(AMOD)
65 FP centers within
9 regions
FP patients 55–64 9,8992 PC 2002 732
TC 236
Program FS Un’occhiata ti salva
la vita
Veneto Residential population
of 1 local health unit
60 5,000 LG 2003 1,600
Research FOBt SCORE 3 Biella, Florence.
Milan, Rimini,
Turin, Verona
Resident population 55–64 122,000 LG, PC 2003 1,965
FS 1,944
TC 1,597
Program FOBt NHS Funded Regional
Screening Program
(Prevenzione Serena)
Turin, Novara Resident population 58 17,900 LG 2003 5,333
FS Turin Resident population 59–69 125,000 2004 3,284
Norway Research FS only NORCCAP-1 Oslo, Telemark Resident population 50–64 100,000 CG, PC 1999 6,695
FS1
FOBt
6,266
Poland Program TC Colonoscopic CRC
Screening
All FP patients 50–65 6,500,000 CG 2000 30,360
Spain Pilot FOBt Catalan CRC Pilot
Screening Programme
Catalonia, l’Hospitalet Resident population 50–69 69,000 LG 2000 10,962
Research FOBt Sigmoidoscopy
Screening Research
Project
Catalonia, Vilafranca
del Penede`s
Resident population 50–69 4,726 LG 2004 322
FS 2,023 1,084
Switzerland Research FOBt – Glarus, Vallee du
Joux, Uri
Resident population 50–80 20,000 O 2000 297
FS 112
TC 2,044
FS1
FOBt
278
1
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TABLE I – A DESCRIPTION OF EACH INITIATIVE, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH ORGANIZATION WHERE POSSIBLE, 2004 (CONTINUED)
Country Initiative
type
Modality Name of initiative Region(s) Target population Age range
Target
population
in age range
Funding
source
Year
activity
began
Total screening
episodes before
May 2004
United
Kingdom
Research FOBt The Nottingham
CRC Screening
Trial
Nottingham, England FP patients 45–74 153,0002 CG 1981 134,128
Research FS UK FS Screening
Trial
14 areas in England,
Scotland and Wales
FP patients 55–64 376,000 CG, PC 1996 40,674
Pilot FOBt The UK Pilot of CRC
Screening
England (3 areas) and
NE Scotland
(2 areas)
Resident population 50–69 476,000 CG 2000 260,000
Research FS Nurses Led FS
Screening Study
Harrow, North
London
FP patients 60–64 500 PC 2003 150
THE AMERICAS
Canada Program FS Colon Cancer
Detection Clinic
Ontario FP patients 501 500,000 HI 1999 1,865
Pilot FOBt Ontario FOBT Pilot
Study
Ontario 6 regions of FP
patients, public
health units
50–75 440,000 LG 2004 Not known
United States
of America
Research FS PLCO Cancer
Screening Trial
10 states 10 Clinical Centers 55–74 154,000 CG 1993 64,700
Program FS CoCaP (Kaiser
Permanente)
Northern California HMO members 501 500,000 CG,
HMO, O
1994 350,000
Pilot FOBt FOBt in Veterans
Affairs
All Veterans Affairs
patients
501 30,000 CG 2000 Not known
Research TC National Colonoscopy
Study (Phase I)
3 states HMO members,
wellness clinic,
resident
population
50–64 975,000 CG 2000 622
WESTERN PACIFIC
Australia Pilot FS FS for CRC in Average-
Risk Subjects
Fremantle, WA Resident suburban
population
55–64 80,000 LG 1995 3,500
Research FOBt Relative performance
and acceptability
of FOBt types
Adelaide, SA Southern residential
population
501 100,000 CG, PC, O 1997 4,165
Pilot FOBt The Australian Bowel
Cancer Screening
Pilot
Melbourne, Vic;
Adelaide SA;
MacKay, Qld
Resident population 55–74 57,000 LG, CG 2002 25,840
Hong Kong Research TC Screening for CRC in
Chinese
All Resident population 50–70 480,000 PC 2000 510
Japan Program FOBt National CRC
Screening Program
All National health
insurance holders
401 35,000,000 CG, S 1992 6.4 million
Taiwan3 Pilot FOBt Keelung Community-
based Integrated
Screening
Kelung, Northern
Taiwan
Resident population 50–79 81,000 LG 1999 22,716
CG, central government; FOBt, fecal occult blood test; FP, family practitioner; FS, ﬂexible sigmoidoscopy; HI, health insurance; HMO, Health Maintenance Organization; LG, local govern-
ment; O, other; PC, private/charity; S, self-funded; TC, total colonoscopy.
1The number of screening episodes at the end of 2004.–2Size of trial population.–3Not a country deﬁned in the WHO regions, but is located in the Western Paciﬁc.
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governments. Forty-six percent of the initiatives were funded only
by government funds, and 31% were funded by the government
and at least one other source. Initiatives were funded to a lesser
extent by charities, health insurance and self-funding. A very
small contribution came from industry or other private sources.
Modality analysis
We gathered information on 3 screening modalities: FOBt (Ta-
ble IIa), FS (Table IIb) and TC (Table IIc). Seven initiatives used
more than 1 modality or combination of modalities. Due to differ-
ent protocols, each activity was described separately, which
resulted in 45 activities overall.
Of the 45 activities, 22 were using FOBt only. In addition, 2
research projects, 1 in Norway and 1 in Switzerland, used FOBt in
combination with FS. Fourteen were using a gFOBt only, 9 used a
fecal immunochemical test (FIT) only and 1, an Australian
research project, used both types. Fourteen of the FOBt activities
used biennial screening, 8 screened annually, and 2 screened once
only during the study period.
The age groups of the target populations varied widely.
Although all FOBt activities included adults aged 59–64 years,
some enrolled participants in their 40s. Some activities had no
upper age limit, while others ended recruitment between ages 64
and 80. Dietary restriction was common for those using gFOBt,
with counseling to remove vitamin C, red meats and nonsteroi-
dal anti-inﬂammatory drugs from the diet prior to stool samples
being taken. Every activity used colonoscopy for investigation
after a positive FOBt result. The deﬁnition of a positive test
varied. For example, some activities recorded a participant as
positive if 1 or more test squares were positive on the FOBt
card (pilot studies in particular). Other activities deemed a par-
ticipant as positive if 5 or more squares on multiple cards were
positive.
Fourteen of the initiatives were using FS only as their screening
modality. In addition, 1 initiative in Norway and 1 in Switzerland
used FS in combination with FOBt. Nine of these 16 activities
were ‘‘once only’’ screening, although whether this was offered at
a particular age (58 or 60 years old) or to an age range (50–64
years old) varied. Six of the activities offered screening every 5
years; one, the Colon Cancer Prevention Program (CoCaP) in
Northern California, offered screening every 10 years. Many of
the activities used a home-based enema administered by the
patient as their bowel preparation, whereas Australia, Norway and
Switzerland routinely used enemas in the screening unit. The
CoCaP also used laxatives as part of its bowel preparation.
Nurses performed endoscopy in a program in Ontario, Canada
and a research study in the United Kingdom. Nurses, gastroenter-
ologists or primary care practitioners performed endoscopy in the
U.S. Prostate, Lung, Colon and Ovarian (PLCO) cancer screening
trial and the CoCaP program. Elsewhere, gastroenterologists and
(to a lesser extent) surgeons performed the procedure.
Most activities had clear protocols for polyp removal and crite-
ria for referral for a colonoscopy. In Australia (the pilot study),
Belgium, Canada, Norway, Switzerland and the U.S. PLCO trial,
polyps were not removed during FS and patients were referred for
colonoscopy.
Six activities used colonoscopy as a screening technique; 3 on a
once-only basis, 1 at 5-year intervals, and 2 at 10-year intervals.
All colonoscopy activities offered screening to participants aged
55–64; however, the age at screening ranged from 50 to 80,
depending on the activity. Colonoscopies were routinely con-
ducted in the hospital, except in the Swiss research project (in
which they also were carried out in a doctor’s ofﬁce) and in the
TABLE IIa – A DESCRIPTION OF EACH ACTIVITY, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH
ORGANIZATION WHERE POSSIBLE, 2004. FOBT PROTOCOL
Country, region (initiative) Type of
initiative
Type of test Brand name of test Screening
interval
Number of
bowel
movements
sampled
Total samples
Routine
dietary
restriction
EUROPE
Czech Republic
(National study)
Program G Hemoccult Biennial 3 3 Yes
Denmark, Funen Research G Hemoccult II Biennial 3 6 Yes
France (National pilot) Pilot G Hemoccult Biennial 3 6 No
France, Burgundy Research G Hemoccult Biennial 3 6 No
Israel (National study) Program G Hemoccult SENSA Annual 3 6 Yes
Italy (SCORE 2) Pilot I RPHA immudia Biennial 1 1 No
Italy, Tuscany Program I Alpha Wasserman Biennial 1 1 No
Italy (AMOD) Research G Hemoccult SENSA II Annual 3 6 Yes
Italy, Veneto Program I Alpha Wasserman, Sentinel Biennial 1 1 No
Italy (SCORE 3) Research I RPHA immudia Biennial 1 1 No
Italy (Prevenzione Serena) Program I Alpha Wasserman Biennial 1 1 No
Norway (NORCCAP-1)1 Research I FlexSure OBT Once 3 3 No
Spain, Catalonia Pilot G Hema Screen Biennial 3 6 No
Spain, Catalonia Research G Hema Screen Biennial 3 6 No
Switzerland Research G Hemoccult Annual 3 3 No
Switzerland1 Research G Hemoccult Annual 3 3 No
United Kingdom, Nottingham Research G Hemoccult Biennial 3 6 Yes
United Kingdom,
England and Scotland
Pilot G Hema Screen Biennial 3 6 No
THE AMERICAS
Canada, Ontario Pilot G Hemoccult II Once 3 6 No
United States of America
(Veterans Affairs)
Pilot G Hemoccult II Annual 3 3 No
WESTERN PACIFIC
Australia, Adelaide Research G, I Hemoccult, InSure Annual 3 3 Yes
Inform 2 2 No
Australia (Pilot) Pilot I Magstream HemS, Inform Biennial 2 2 No
Japan Program I Not speciﬁed Annual 2 2 No
Taiwan2 Pilot I Eiken Annual 1 1 No
G, guaiac; I, immunochemical.
1In combination with ﬂexible sigmoidoscopy.–2Not a country deﬁned in the WHO regions, but is located in the Western Paciﬁc.
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TABLE IIb – A DESCRIPTION OF EACH ACTIVITY, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH ORGANIZATION WHERE POSSIBLE, 2004. FLEXIBLE
SIGMOIDOSCOPY PROTOCOL
Country, region
(initiative)
Type of
initiative
Screening
interval
Discipline of
endoscopist
Where is screening
conducted?
Bowel
preparation
Bowel
preparation
location
Criteria for polyp
removal at
sigmoidoscopy
Criteria for colonoscopy
EUROPE
Belgium Research Every 5 years G Hospital Enema Home None removed 51 adenomas, adenomas  10 mm, adenomas with
>25% villous structure, high-grade dysplasia
Italy (SCORE) Research Once G Hospital Enema Home Polyps 5 mm Polyps >5 mm , high risk small polyps
Italy (SCORE 2) Pilot Once G, S Hospital Enema Home Polyps <10 mm 3 adenomas <10 mm, polyps 10 mm, CRC, polyps
with severe dysplasia or villous component <20%
Italy, Veneto Program Once G Hospital Enema Home Polyps <6 mm 3 adenomas <10 mm, polyps 10 mm, CRC, polyps
with severe dysplasia or villous component <20%
Italy (Prevenzione
Serena)
Program Once G, S Hospital Enema Home Polyps <10 mm 3 adenomas <10 mm, polyps 10 mm, CRC, polyps
with severe dysplasia or villous component <20%
Italy (SCORE 3) Research Once G, S Hospital Enema Home Polyps <10 mm 3 adenomas <10 mm, polyps 10 mm, CRC, polyps
with severe dysplasia or villous component <20%
Norway1 Research Once M Hospital Enema Unit None removed Polyp >10 mm and any adenoma
Spain Research Once G Hospital Enema Home Polyps <10 mm 31 adenomas, polyps 10 mm, tubulovillous or villous
histology, or severe dysplastic or neoplastic polyp
Switzerland Research Every 5 years G Hospital, ofﬁce Enema Unit None removed Any polyp
Switzerland1 Research Every 5 years G Hospital, ofﬁce Enema Unit None removed Any polyp
United Kingdom
(Nurse-led Study)
Research Once N Hospital Enema Home Polyps <10 mm 31 adenomas, polyps >10 mm
United Kingdom
(Flexisig trial)
Research Once G, S Hospital Enema Home Polyps <10 mm 31 adenomas, 201 hyperplastic polyps above the
distal rectum, polyps 10 mm, tubulovillous or
villous histology, severe dysplasia
THE AMERICAS
Canada, Ontario Program Every 5 years N Hospital Enema Home None removed Any polyp
United States of
America (PLCO)
Research Every 5 years G, N Hospital, ofﬁce Enema Home None removed As per FP
United States of
America (CoCaP)
Program Every 10 years G, PCP, N Hospital Enema, laxative Home Polyps <5 mm 21 tubulovillous adenomas (1 if family history),
polyps >10 mm, with villous histology or
high grade dysplasia
WESTERN PACIFIC
Australia, Fremantle Pilot Every 5 years G, S Hospital Enema Unit None removed Adenomas, multiple hyperplastic polyps
G, gastroenterologist; M, medics: consultants and specially trained junior doctors; N, nurse; P, program; PCP, primary care practitioner; PS, pilot study; RP, research project; S, surgeon.
1In combination with fecal occult blood tests.
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U.S. National Colonoscopy Study (in which colonoscopies were
performed in an outpatient endoscopy unit). In all studies, gastro-
enterologists performed the screening colonoscopy. In Poland,
surgeons were also able to perform colonoscopy.
Initiative designs
Ten routine population screening programs were identiﬁed in 7
countries. Eight countries (9 initiatives) were running pilot studies,
and research projects continued in 11 countries (16 initiatives).
Italy was running a number of different local programs, rather
than a single national program. Research projects coexisted in
countries that were operating pilot projects or full programs.
Programs
Five of the identiﬁed programs offered FOBt only, 3 offered FS
only, 1 offered TC only and 1 program in Italy (Prevenzione Ser-
ena) offered both FOBt and FS (Table IIIa). The most established
programs were in Japan and Israel, as well as CoCaP in the United
States. These programs began recruitment in 1992, 1993 and
1994, respectively. A variety of recruitment methods were used; a
mailed invitation, usually personalized, was the most popular
method where population registers were available. Other methods
included referral by a family practitioner and the use of media.
Practice varied as to whether the written results were sent to the
patient, the patient’s usual family physician, or both. All programs
had mechanisms to follow up all positive FOBt or FS results,
except for the Czech Republic and the CoCaP program. All pro-
grams had evaluation systems in place.
Pilot studies
Seven of the identiﬁed pilot projects offered FOBt, 1 offered FS
and 1 in Italy (SCORE 2) offered both (Table IIIa). All 9 projects
had some form of population register available, and systems in
place for invitations and reminders (except for Canada, the U.S.
Veterans Affairs (VA) pilot study and Taiwan). All studies had
structured systems in place for evaluations, and 7 sent the results
to both the patient and their usual doctor. The exceptions were
Canada (only the patient’s doctor received the results) and Taiwan
(only the patient received the results). Canada, the U.S. VA pilot
study and Taiwan had no mechanisms to follow up a positive test.
Research projects
Four of the identiﬁed research projects offered FOBt only, 5
offered FS only, 2 offered TC only and 5 offered a combination of
2 or 3 modalities (Table IIIa). Half of the population in the Norwe-
gian study received FOBt screening in combination with FS. All
except Hong Kong used some form of population register for
recruitment. In addition, the majority of the initiatives had systems
in place for evaluation, as well as routinely sending reminders to
nonresponders. All projects reported normal and abnormal results
to the patients. Eleven also reported normal results to physicians;
13 reported abnormal results to physicians.
Most of the projects were randomized controlled trials. Switzer-
land and Hong Kong described their studies as cohort studies; Bel-
gium and the nurse-led study in the United Kingdom were
described as feasibility studies (Table IIIb). It was in these initia-
tives that the greatest mix of protocols was found, with various
combinations of modalities being used.
Discussion
The publication during the early and mid 1990s of trial and
study results demonstrating the efﬁcacy of screening for CRC had
led, by the early years of the 21st century, to the implementation
of a number of diverse screening initiatives in several countries of
the world, in particular those with a high incidence of CRC. This
is the ﬁrst investigation describing the delivery of screening proto-
cols to various populations.
Of the 17 countries identiﬁed by the ICRCSN that had begun
organized CRC screening prior to May 2004, only 4 provided
national programs. Three of these programs offered FOBt (Czech
Republic, Israel and Japan) as their screening modality; one,
Poland, offered TC. Six other programs (4 in Italy) were offered
only at a regional level. In addition, there were 4 central govern-
ment-funded pilot studies reported (France, United Kingdom,
United States and Australia), most of which have subsequently
progressed into national programs [France, United Kingdom
(http://www.cancerscreening.nhs.uk/bowel/index.html) and the
U.S. VA program]. Several of the other pilot studies had local
government funding and may advance to regional programs in the
future.
Fecal occult blood testing was the most frequently used screen-
ing modality, possibly because of the encouraging results in terms
of acceptability, feasibility and efﬁcacy from previous randomized
clinical trials.4,6,8 In 1999, FOBt was accepted by the European
Union as the standard for CRC screening.20 Several initiatives
have used protocols based on those from the randomized clinical
trials (for example, timing of screening, use of gFOBt, taking 2
samples from 3 consecutive bowel movements and dietary restric-
tion). Some more recent FOBt initiatives have used FIT rather
than gFOBt.
FS also was frequently used. Although large clinical trials of FS
screening do exist (none are completed), they are more recent than
those using FOBt, and there are fewer, if any, initiatives following
trial protocols.11,12,14,15 Bowel preparation for FS screening was
fairly uniform, in that every participant had an enema that was
typically self-administered at home. Screening typically occurred
only once, but 5-year and 10-year intervals also were used. Refer-
ral for colonoscopy varied from any polyp being identiﬁed to cri-
teria based on the number, size and histopathology of polyps
found through FS.
TC was used in only 6 initiatives (1 program and 5 research proj-
ects), even though it is considered the ‘‘gold standard’’ for CRC
identiﬁcation. Gastroenterologists always performed TC, except in
Poland where surgeons also performed the procedure. Colonoscop-
ies were conducted in a hospital for all initiatives, as well as in the
TABLE IIc – A DESCRIPTION OF EACH ACTIVITY, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH
ORGANIZATION WHERE POSSIBLE, 2004. TOTAL COLONOSCOPY PROTOCOL
Country, region (initiative) Type of initiative Screening interval Discipline of endoscopist Where is screening conducted?
EUROPE
Italy (AMOD) Research Once G Hospital
Italy (SCORE 3) Research Once G Hospital
Poland Program Every 10 years G, S Hospital
Switzerland Research Every 10 years G Hospital, ofﬁce1
THE AMERICAS
United States of America (National Study) Research Once G Outpatient endoscopy unit
WESTERN PACIFIC
Hong Kong Research Every 5 years G Hospital
G, gastroenterologist; S, surgeon.
1Ofﬁce of the endoscopist.
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TABLE IIIa – INITIATIVE DESIGNS, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH ORGANIZATION WHERE POSSIBLE, 2004
Country, region (initiative) Modality
Invitations and reminders
Structured
system
for evaluation
Written conﬁrmation
of normal and
abnormal
results
Mechanism to
follow up
positive testSystem
1 Population
register2
Method Are reminders sent?
PROGRAMS
EUROPE
Czech Republic FOBt No None Opportunistic: When visit FP,
public campaign
No Yes Doctor No
Israel FOBt Yes HMO Mailed invite and post card to
order test kit
No Yes Doctor Yes
Italy, Tuscany FOBt Yes FPR, PR Mailed personal invite and leaﬂet
from FP, media
Yes Yes Patient Yes
Italy, Veneto FOBt Yes FPR, PR Mailed personal invite and leaﬂet
from FP, media
Yes Yes Doctor, Patient Yes
Italy, Veneto FS Yes FPR, PR Mailed personal invite, leaﬂet and
appointment date from FP, age
dependent self-referral, media
Yes Yes Doctor, Patient Yes
Italy (Prevenzione Serena) FS Yes FPR, PR Mailed personal invite, leaﬂet and
preﬁxed appointment from FP,
age dependent self-referral,
media
Yes Yes Doctor, Patient Yes
FOBt Mailed personal invite and
leaﬂet from FP, media
Poland TC No None Opportunistic: When visit FP,
media
No Yes Patient N/A
THE AMERICAS
Canada FS No None Opportunistic: when visit FP No Yes Doctor Yes
United States of America (CoCaP) FS No None Opportunistic: when visit FP No Yes Doctor, Patient No
WESTERN PACIFIC
Japan FOBt Yes PR, IR Opportunistic: news letter issued
by local government
No Yes Patient Yes
PILOT STUDIES
EUROPE
France FOBt Yes IR FP if visit FP, mailed invite
otherwise
Yes Yes Doctor, Patient Yes
Italy (SCORE 2) FOBt Yes FPR, PR Mailed personal invite from FP,
leaﬂet and test kit mailed to 1st
arm in 1st round
Yes Yes Doctor, Patient Yes
FS Mailed personal invite from FP,
leaﬂet, and preﬁxed
appointment
Spain FOBt Yes FPR Mailed invite and leaﬂet Yes Yes Doctor, Patient Yes
United Kingdom, England
and Scotland
FOBt Yes LHA Mailed invite, then test kit, media Yes Yes Doctor, Patient Yes
THE AMERICAS
Canada FOBt Yes FPR Opportunistic: face-to-face, media No Yes Doctor No
United States of America (VA) FOBt Yes VAR FP receive annual computer
prompt when patient is visiting
No Yes Doctor, Patient No
WESTERN PACIFIC
Australia, Fremantle FS Yes ER Mailed invite Yes Yes Doctor, Patient Yes
Australia (Pilot) FOBt Yes IR Mailed invite, booklet,
questionnaire, consent form and
test kit
Yes Yes Doctor, Patient Yes
Taiwan3 FOBt Yes PR, PSR Telephone invite No Yes Patient No
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TABLE IIIa – INITIATIVE DESIGNS, PRESENTED ALPHABETICALLY BY COUNTRY WITHIN REGIONS DEFINED BY THE WORLD HEALTH ORGANIZATION WHERE POSSIBLE, 2004 (CONTINUED)
Country, region (initiative) Modality
Invitations and reminders
Structured
system
for evaluation
Written conﬁrmation
of normal and
abnormal
results
Mechanism to
follow up
positive testSystem
1 Population
register2
Method Are reminders sent?
RESEARCH PROJECTS
EUROPE
Belgium FS Yes SCR Opportunistic: when visit FP Yes Yes Doctor, Patient Yes
Denmark, Funen FOBt Yes PR Mailed invite and test kit Yes Yes Doctor, Patient4 Yes
France, Burgundy FOBt Yes IR Mailed invite and leaﬂet Yes Yes Doctor, Patient Yes
Italy (SCORE) FS Yes FPR Mailed personal invite and
preﬁxed appointment from FP
Yes Yes Doctor, Patient Yes
Italy (AMOD) FOBt Yes FPR Personal mailed invite from FP Yes
(telephone)
Yes Doctor, Patient No
TC N/A
Italy (SCORE 3) FOBt Yes FPR, PR Personal mailed invite from
FP, media in 1 region
Yes Yes Doctor, Patient Yes
FS Personal mailed invite and
preﬁxed appointment
from FP, media in 1 region
Yes
TC Personal mailed invite and
preﬁxed appointment
from FP, media in 1 region
N/A
Norway FS only Yes PR Mailed invite and appointment
date
Yes Yes Patient Yes
FS 1 FOBt Mailed invite, test, and
appointment date
Spain FS, FOBt Yes FPR Mailed invite and leaﬂet Yes Yes Doctor, Patient Yes
Switzerland FOBt Yes PR Mailed invite, public lectures,
media
Yes Yes Patient Yes
FS Yes Yes
TC No N/A
FS 1 FOBt Yes Yes
Nottingham,
United Kingdom
FOBt Yes FPR Personal mailed test kit and
invite from FP
No Yes Doctor, Patient Yes
United Kingdom
(Flexisig)
FS Yes FPR Mailed invite with preﬁxed
appointment
Yes Yes Doctor, Patient Yes
United Kingdom
(Nurse-led study)
FS Yes FPR Mailed leaﬂet, followed by
mailed invite, appointment
given, enema posted
Yes Yes Doctor, Patient Yes
THE AMERICAS
United States of America
(PLCO)
FS Yes ER Mailed invite and leaﬂet, media Yes Yes Doctor, Patient Yes
United States of America
(National TC Study)
TC Yes HMO, PR,
SCR
Mailed invite, telephone,
face-to-face
Yes Yes Doctor, Patient N/A
WESTERN PACIFIC
Australia, Adelaide FOBt Yes ER Mailed invite and test kit Yes Yes Doctor, Patient5 Yes
Hong Kong TC No None Health Exhibition, volunteer No No Doctor, Patient N/A
ER, electoral roll; FOBt, fecal occult blood test; FP, family physician; FPR, family physician registry; FS, ﬂexible sigmoidoscopy; HMO, Health Maintenance Organization; IR, insurance regis-
try; LHA, local health authority; N/A, not applicable; PR, population registry (e.g. national registry); PSR, pap smear registry; SCR, screening clinic registry; TC, total colonoscopy; VAR, veteran
affairs register.
1Is a structured information system used to manage invitations and reminders?–2A register that contains a list of possible participants, such as a population census.–3Not a country deﬁned in the
WHO regions, but is located in the Western Paciﬁc.–4Doctor received only normal results.–5Doctor received only abnormal results.
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ofﬁce of the gastroenterologist in Switzerland and in an outpatient
endoscopy unit in the United States. Once-only screening was most
common, however, 5-year screening was conducted in Hong Kong,
and 10-year screening in Poland and Switzerland.
At this stage there appears to be no preferred method of con-
ducting CRC screening, deﬁning a positive screening test for pur-
poses of initiating follow-up, and for follow-up itself. Information
was collected in the survey on screening performance and out-
comes and quality assurance measures; however, because of the
lack of standardized deﬁnitions, more information is required on
these topics before conclusions can be drawn. Consequently, con-
tinued activity for the ICRCSN will concentrate on the develop-
ment of quality assurance protocols and indicators to allow com-
monly understandable results to be reported across all participants
in the Network.
Unfortunately, not all organized CRC screening initiatives in
existence in 2003/2004 were included in this report. Some initia-
tives were not brought to the attention of the ICRCSN until after
data collection. We will continue to include initiatives as they are
identiﬁed.
In conclusion, the knowledge gained from programs, research
projects and pilot studies can be shared and used in the advance-
ment of CRC screening. The establishment of the ICRCSN has
made the sharing of valuable information possible and has created
a connection among initiatives across the world. It is the intention
that preferred protocols will be established in the future, establish-
ing uniform screening methodologies and guidelines that can be
followed by future initiatives. The continued support of the Net-
work’s members will help both new and existing initiatives reach
their full potentials.
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